Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I meant valuation for ONT of course
agree with DD77, valuation for IPO will be >>$3.4bn. More like £5-7bn (circa $8bn). That's based on their sales and CAGR, as well as increased global market penetration compared to main benchmark, pacific bioscience, which is currently valued at $6.3bn.
ten percent coming ,nice
IPO • LON
IP Group Plc
GBX 137.20
8.03%
+10.20 Today
Sep 1, 3:29:28 PM UTC+1 · GBX · LON · Disclaimer
do you know how to value a company then, just be happy with what you get, lol
$3.4 billion? It's worth a lot more than that, probably double
Oxford Nanopore to launch $3.4 bln London IPO in coming weeks - sources
Wed, 1st Sep 2021 15:00Thomson Reuters
By Abhinav Ramnarayan
LONDON, Sept 1 (Reuters) - Oxford Nanopore, a provider of
rapid COVID-19 tests to the UK’s national health service, is
working with banks to launch an initial public offering (IPO) on
the London Stock Exchange in the coming weeks - a deal that
would strengthen Britain's efforts to lure life science
businesses to its main market.
year high today ,nice
Still the foothills, nowhere near the peak here folks. Expect many more days like today ahead! Penny is finally dropping about ONT valuation and what it will mean for IP group NAV!!
We could hit a new 52 week high at this rate
yes, that is correct and have a look at the rest of the markets,nice
Indices Value Chg %
FTSE 100 7,178.58 58.88 0.83%
FTSE 250 24,276.63 174.44 0.72%
FTSE 350 4,156.93 33.48 0.81%
FTSE All-Share 4,142.61 32.65 0.79%
FTSE Small Cap 7,650.59 23.13 0.30%
somethings happening sp is relentless
Starting to see some bigger volume coming through - presume linked to knowledge of or in anticipation of nanopore IPO guidance. Shareprice only heading in one direction!
Friday well after hours looks to me like it could easily have been an early 'buy'. If it was a sell, it would have moved the SP much more.
Can't see it being September - they'd need to have provided the market with guidance by now if it was going to be next month!
For what it’s worth, my prediction is they’ll list in Sept or Oct, with valuation supported by strong H1 and bullish genomics sector (CRISPR/Covid effect etc). Not the end of the world if it’s 2022, but I’d be surprised. I think retail investors are underestimating the HUGE interest in ONT from investment institutions across the globe
My sense is they're nervous about the external environment for IPOs atm, which is why it's already been delayed but also because they're happy building value as things stand and in no rush. Could be wrong but I think it will get pushed out to H1 22. I agree that £5-7bn is more realistic valuation
DD77 - ONT have acknowledged they don’t expect revenue from lampore beyond early 2021, but likely sustained revenue from SarsCov2 genomic surveillance. I noted that indicative growth of overall LR sequencing revenues in H1 2021 are >80%, which is great and a sign of CAGR that can be achieved over coming years! No reason why IPO shouldn’t go ahead as planned, changes to board and exec team point in this direction, what is your basis to doubt it? At IPO, I think valuation of £4bn is conservative (realistically more like £5-7bn. Exciting few weeks ahead…
Interesting reading, thanks for sharing. Despite the astonishing progress in revenue, losses are still quite high. It'll be interesting to see how much growth they see in their Lampore Covid testing kit, as UK has discontinued the contract.
I'm not convinced we'll see an IPO this year.
Looks like you're right on the SP danrh - we're pushing on towards the 52 week high now. All looks very positive here
Oxford Nanopore Technologies 2020 Revenues More Than Double
Aug 16, 2021 | staff reporter
Remove from my reading list
NEW YORK – Oxford Nanopore Technologies reported earlier this month that its 2020 revenues grew 119 percent, driven by growth in its core tools market as well as COVID-19 testing revenue. The company also said that so far in 2021, revenue growth in its core business has been strong.
In a filing with Companies House, a UK government agency, Oxford Nanopore reported 2020 revenues of £113.9 million ($157.6 million), up from £52.1 million in 2019. Life science research tools revenues were £65.5 million, up 26 percent, while COVID-19 testing, which did not exist in 2019, brought in revenues of £48.3 million.
Product revenues were £106.1 million, while service revenues were £4.9 million, and revenues from lease income were £2.9 million. Revenues from the UK were £52.9 million; from the US, £16.4 million; Europe, £18.9 million; China, £7.7 million; Japan, £4.2 million; and the rest of the world, £13.8 million.
The firm reported a net loss of £61.2 million, or £0.002 per share, compared to a net loss of £72.2 million, or £0.0025 per share, in 2019. The loss from exchange differences on translation of foreign operations was £429,000, compared to £133,000 the year before.
Oxford Nanopore's R&D spending grew 20 percent to £48.6 million from £40.5 million in 2019, while SG&A expenses were £71.4 million, up 8 percent from £66.1 million a year ago.
"The year brought operational challenges for Oxford Nanopore due to COVID-19, but the business responded strongly," the firm wrote.
The company raised £161.3 million in 2020, compared to £200,000 the year before, including a private placement of shares from December 2019 and £132.8 million raised via private placements in May and September 2020. Oxford Nanopore said it used the funds to grow its commercial team, support R&D, and scale up biologics manufacturing capabilities.
The firm ended the year with 527 employees — 235 in R&D, 186 in SG&A, and 106 in production — and £80.9 million in cash and cash equivalents.
The firm did not provide specific 2021 guidance but said that the "general level of activity in 2021 is expected to increase, compared to 2020." Revenue growth in its core business "has been strong and accelerating in the first six months of 2021, compared to the same period in 2020, with indicative growth of greater than 80 percent," the firm said.
Oxford Nanopore also said that it raised another £202 million from private placements in April of this year (in May, one of the firm's early investors had said Oxford Nanopore had raised £195 million). In March, the firm announced plans to go public in the second half of the year; however, in the filing it said that "the timing of the IPO is not under the control of the company, due to market condition."
In April, the UK Department of Health and Social Care terminated a contract for LamPore SARS-CoV-2 testing k
Always good news to see the SP going up.
I didn't think I was being dismissive - there's plenty of hot-air speculators on these boards - all I wanted to see was some meat on the bones and a line-in-the-sand to measure against.
As you wrote: "I'm just a random stranger to you, and don't expect anyone to trust my opinion".
So we’re up 18% since my post on 20th July. I’ll await your acknowledgement @Monty888 and @moorhey after being so dismissive ??
Looks like we’ll see manipulation to hold/drop the price this morning so MFs and HFs can buy in at a discount! Have seen it so many times. We’ll end green! +5% is my guess
Half-yearly result don’t get much better than this!
Half-year highlights
• Strong Return on Hard NAV1 of £117.9m, or 9%, (HY20: £14.2m; FY20: £189.5m)
• Hard NAV2 of £1,439.3m or 135.4 pence per share (HY20: £1,156.4m or 108.8pps; FY20: £1,331.5m or 125.3pps)
• Cash realisations of £111.4m (HY20: £113.7m; FY20: £191.0m)
• Sustained investment into portfolio: £69.5m into 41 companies (HY20 £36.9m; FY20: £67.5m)
• Interim dividend of 0.48p per share and £20m allocated to buying back the Group’s shares
https://us02web.zoom.us/webinar/register/WN_DCpwJH6iTC-UG208DshGrg
Registration for results webinar